Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 22, 2023, Eloxx Pharmaceuticals, Inc. (the "Company") held its 2023 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a total of 1,252,975 shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), were present by valid proxy, representing approximately 57.83% of the Company's outstanding voting power as of the April 24, 2023 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company's definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2023.
Proposal 1 - Election of five (5) directors to hold office until the Company's annual meeting of stockholders to be held in 2024 and until his or her respective successor is duly elected and qualified.
Votes Votes
NOMINEE Votes FOR AGAINST ABSTAINED Broker Non-Votes
Tomer Kariv 557,994 5,140 42,001 647,840
Sumit Aggarwal 511,136 4,776 89,223 647,840
Lindsay Androski, JD, MBA 559,991 3,197 41,947 647,840
Steven Rubin 509,103 7,248 88,784 647,840
Alan Walts, Ph.D. 559,951 3,312 41,872 647,840
Proposal 2 - Ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 1,181,736 23,057
48,182 0
Proposal 3 - Advisory vote on the compensation of the Company's named executive officers.
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes
550,254 12,373 42,508 647,840
Based on the foregoing votes, each of the director nominees was elected, and Proposals 2 and 3 were approved.
© Edgar Online, source Glimpses